Module 10: Cardiac Amyloidosis

Screening, diagnosis, and management of ATTR and AL cardiac amyloidosis. Tafamidis (ATTR-ACT), Tc-PYP scintigraphy, genetic testing, and contraindicated medications.

1.Classification 2.Diagnostics 3.Risk 4.Stage A 5.Stage B 6.HFrEF GDMT 7.Devices 8.HFmrEF 9.HFpEF 10.Amyloidosis 11.Advanced HF 12.Comorbidities 13.Special Pops

Evaluate for cardiac amyloidosis. Consider in patients with unexplained LVH, HFpEF with red flags, or neuropathy.

Known or Suspected Cardiac AmyloidosisLow-Voltage ECGApical Sparing on Strain

NYHA Class

Monoclonal Protein

PYP Grade

IMPORTANT: This software is clinical decision support (CDS) intended for use by licensed healthcare professionals under Section 520(o)(1)(E) of the Federal Food, Drug, and Cosmetic Act. It is not intended as a medical device. All recommendations are derived from the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure and must be independently verified by the treating clinician before any clinical action. AI-generated content (including extracted data and clinical notes) is produced by large language models and may contain errors, omissions, or hallucinations — clinician review is mandatory. Patient data entered into the calculator is processed entirely in the browser; AI features process data server-side under a signed HIPAA Business Associate Agreement with no data retention. AI-HEART Lab, its affiliates, and contributors assume no liability for clinical decisions made using this tool. By using this tool, you acknowledge these limitations and accept full responsibility for clinical decisions.